ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Add as a preferred source on Google
BOSTON, March 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2017.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 7184949. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on March 6, 2018 through March 13, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 7184949.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
